Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open Label, Non-Randomised Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Multiple Oral Doses of Cediranib (AZD2171, RECENTINÔ), in Patients With Advanced Solid Tumours

NCT00750425 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00750425
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00750425 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open Label, Non-Randomised Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Multiple Oral Doses of Cediranib (AZD2171, RECENTINÔ), in Patients With Advanced Solid Tumours
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2008
Completion date
January 31, 2011
Enrollment
46 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors